What is Redx?
Headquartered at Alderley Park, Cheshire, Redx Pharma operates as a clinical-stage biotechnology entity specializing in the discovery and development of highly targeted, small molecule therapeutics. Since its inception in 2010, the firm has cultivated a robust portfolio targeting cancer, fibrotic disease, and cancer-associated fibrosis. Its scientific strategy centers on the development of selective inhibitors, including ROCK2, ROCK1, Porcupine, and Pan-RAF programs, alongside advanced Discoidin Domain Receptor (DDR) initiatives. By addressing high-unmet medical needs such as idiopathic pulmonary fibrosis and fibro-stenotic Crohn's disease, Redx Pharma occupies a critical niche in the pharmaceutical value chain, often leveraging strategic partnerships with global industry leaders to facilitate the progression of its assets through late-stage clinical trials.
How much funding has Redx raised?
Redx has raised a total of $51.2M across 2 funding rounds:
Private Equity
$14.2M
Grant
$1M
Private Equity (2016): $14.2M, investors not publicly disclosed
Grant (2017): $1M led by Carb-X
Key Investors in Redx
Carb-X
CARB-X is a global non-profit partnership dedicated to accelerating antibacterial innovation by funding the development of new antibiotics and diagnostics to combat drug-resistant bacteria.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Redx?
Looking ahead, Redx Pharma is positioned to leverage its recent capital influx to deepen its research into Wnt-ligand dependent cancers and other complex pathologies. The strategic roadmap emphasizes the maturation of its clinical pipeline, with a clear objective to achieve definitive proof-of-concept data that will enhance the company's leverage in future licensing negotiations. As the firm continues to refine its small molecule platform, the focus will remain on operational efficiency and the successful execution of its ongoing clinical programs. By maintaining a disciplined approach to R&D, Redx Pharma aims to deliver transformative therapies that address the systemic challenges of antibiotic resistance and chronic fibrotic conditions, ultimately driving long-term value for stakeholders and patients alike.
See full Redx company page
